Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
April 02, 2024 14:36 ET | Harvard Apparatus Regenerative Technology, Inc.
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following...
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
March 28, 2024 08:00 ET | Cocrystal Pharma, Inc.
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
March 26, 2024 17:04 ET | Serina Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the...
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2023 08:30 ET | Imunon, Inc.
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE...
IMUNON’s VP of R&D to Present at the Vaccines Summit-2023
November 14, 2023 09:00 ET | Imunon, Inc.
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON’s PlaCCine modality and its applicability to multiple pathogens LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) --...
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
October 12, 2023 08:01 ET | Ocean Biomedical, Inc.
Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top...
IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
June 27, 2023 12:00 ET | Imunon, Inc.
Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies HUNTSVILLE, Ala.,...
IMUNON CEO Issues Letter to Shareholders
March 01, 2023 08:45 ET | Imunon, Inc.
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
February 27, 2023 08:30 ET | Imunon, Inc.
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON,...
Cocrystal Pharma to Participate in Two Investor Conferences in November
November 02, 2022 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investor conferences as follows: 2022 BioFlorida...